PYCR2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: 293T, HepG2 and K562 cell lysates, Primary antibody: P10375(PYCR2 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10375(PYCR2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10375(PYCR2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

PYCR2 (pyrroline-5-carboxylate reductase 2) is an enzyme encoded by the PYCR2 gene, part of the PYCR family involved in proline biosynthesis. It catalyzes the reduction of pyrroline-5-carboxylate (P5C) to proline, a critical process for cellular homeostasis, collagen synthesis, and redox balance. PYCR2 localizes to mitochondria and is highly expressed in metabolically active tissues, including the brain, linking it to mitochondrial function and energy metabolism. Dysregulation of PYCR2 has been implicated in neurological disorders, such as hypomyelinating leukodystrophy and Alzheimer’s disease, as well as cancer, where proline metabolism supports tumor growth and stress adaptation.

PYCR2 antibodies are immunological tools designed to detect and quantify PYCR2 protein levels in research applications like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies aid in studying PYCR2's role in cellular processes, disease mechanisms, and metabolic pathways. Many PYCR2 antibodies are raised in rabbits or mice using specific antigenic peptides, with validation steps (e.g., knockout controls) ensuring specificity. Recent studies using PYCR2 antibodies have highlighted its interaction with mitochondrial complexes and potential as a biomarker in cancer prognosis. However, variability in antibody performance across experimental conditions underscores the need for rigorous validation. Research on PYCR2 continues to explore its therapeutic potential in metabolic and neurodegenerative diseases.